Development of Korean Version of Heparin-Coated Shunt

헤파린 표면처리된 국산화 혈관우회도관의 개발

  • Sun, Kyung (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Park, Ki-Dong (Korea Institute of Science and Technology) ;
  • Baik, Kwang-Je (Department of Emergency Medicine, Inha University College of Medicine) ;
  • Lee, Hye-Won (Department of Anesthesiology, Korea University Medical College) ;
  • Choi, Jong-Won (Department of Clinical Pathology, Inha University College of Medicine) ;
  • Kim, Seung-Chol (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Kim, Taik-Jin (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Lee, Seung-Yeol (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Kim, Kwang-Taek (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Kim, Hyoung-Mook (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College) ;
  • Lee, In-Sung (Department of Thoracic and Cardiovascular Surgery, Korea University Medical College)
  • 선경 (고려대학교 흉부외과학교실) ;
  • 박기동 (한국과학기술원) ;
  • 백광제 (인하대학교 응급의학과교실) ;
  • 이혜원 (고려대학교 마취과학교실) ;
  • 최종원 (인하대학교 임상병리학교실) ;
  • 김승철 (고려대학교 흉부외과학교실) ;
  • 김택진 (고려대학교 흉부외과학교실) ;
  • 이승열 (고려대학교 흉부외과학교실) ;
  • 김광택 (고려대학교 흉부외과학교실) ;
  • 김형묵 (고려대학교 흉부외과학교실) ;
  • 이인성 (고려대학교 흉부외과학교실)
  • Published : 1999.02.01

Abstract

Background: This study was designed to develop a Korean version of the heparin-coated vascular bypass shunt by using a physical dispersing technique. The safety and effectiveness of the thrombo-resistant shunt were tested in experimental animals. Material and Method: A bypass shunt model was constructed on the descending thoracic aorta of 21 adult mongrel dogs(17.5-25 kg). The animals were divided into groups of no-treatment(CONTROL group; n=3), no-treatment with systemic heparinization(HEPARIN group; n=6), Gott heparin shunt (GOTT group; n=6), or Korean heparin shunt(KIST group; n=6). Parameters observed were complete blood cell counts, coagulation profiles, kidney and liver function(BUN/Cr and AST/ ALT), and surface scanning electron microscope(SSEM) findings. Blood was sampled from the aortic blood distal to the shunt and was compared before the bypass and at 2 hours after the bypass. Result: There were no differences between the groups before the bypass. At bypass 2 hours, platelet level increased in the HEPARIN and GOTT groups(p<0.05), but there were no differences between the groups. Changes in other blood cell counts were insignificant between the groups. Activated clotting time, activated partial thromboplastin time, and thrombin time were prolonged in the HEPARIN group(p<0.05) and differences between the groups were significant(p<0.005). Prothrombin time increased in the GOTT group(p<0.05) without having any differences between the groups. Changes in fibrinogen level were insignificant between the groups. Antithrombin III levels were increased in the HEPARIN and KIST groups(p<0.05), and the inter-group differences were also significant(p<0.05). Protein C level decreased in the HEPARIN group(p<0.05) without having any differences between the groups. BUN levels increased in all groups, especially in the HEPARIN and KIST groups(p<0.05), but there were no differences between the groups. Changes of Cr, AST, and ALT levels were insignificant between the groups. SSEM findings revealed severe aggregation of platelets and other cellular elements in the CONTROL group, and the HEPARIN group showed more adherence of the cellular elements than the GOTT or KIST group. Conclusion: Above results show that the heparin-coated bypass shunts(either GOTT or KIST) can suppress thrombus formation on the surface without inducing bleeding tendencies, while systemic heparinization(HEPARIN) may not be able to block activation of the coagulation system on the surface in contact with foreign materials but increases the bleeding tendencies. We also conclude that the thrombo-resistant effects of the Korean version of heparin shunt(KIST) are similar to those of the commercialized heparin shunt(GOTT).

배경: 흉부대동맥 수술에 사용하는 헤파린 우회도관의 국산화를 위해, 헤파린 표면처리기법 중 물리분산법을 이용하여 제작한 우회도관의 동물실험을 통해 혈전저항성 및 안정성을 증명하고자 하였다. 대상 및 방법: 성견 21마리(17.5∼25 kg)를 대상으로 하행흉부대동맥 우회모델을 만들었다. 사용한 우회도관의 종류에 따라 무처리 우회도관군(CONTROL; n=3), 무처리 우회도관 및 전신 헤파린 처치군(HEPARIN; n=6), Gott 헤파린 우회도관군(GOTT; n=6), 국산 헤파린 우회도관군(KIST; n=6)로 분류하였다. 관찰지표는 말초혈액검사, 혈액응고검사, 신장 및 간기능검사, 표면전자현미경 소견 등이었다. 각 지표는 우회도관의 원위부 대동맥 혈액에서 검사하여 우회 전과 우회 후 2시간 째의 군내 변화와군간 차이를 비교하였다. 결과: 모든 관찰지표의 우회 전 기초치는 군간에 차이가 없었다. 말초혈액검사 중 혈소판치는 HEPARIN군과 GOTT군에서 유의하게 높아졌으나(p<0.05) 군간 차이는 유의하지 않았다. 기타 혈구세포의 변화는 각 군에서 군내변화와 군간차이가 유의하지 않았다. Activated clotting time, activated partial thromboplastin time, thrombin time은 HEPARIN군에서 현저히 증가하였고(p<0.05) 군간차이도 유의하였다(p<0.005). Prothrombin time은 GOTT군에서 유의하게 증가하였으나(p<0.05) 군간차이는 없었다. Fibrinogen은 각 군에서 군내변화와 군간차이가 유의하지 않았다. Antithrombin III는 HEPARIN군과 KIST군에서 유의하게 감소하였고(p<0.05) 군간차이도 유의하였다(p<0.05). Protein C는 HEPARIN군에서 유의하게 감소하였으나(p<0.05) 군간차이는 없었다. Blood urea nitrogen은 HEPARIN군과 KIST군에서 유의하게 증가하였으나(p<0.05) 군간차이는 없었다. Creatinine, aspartate aminotransferase, alanine aminotransferase는 각 군에서 군내변화와 군간차이가 유의하지 않았다. 표면전자현미경 소견에서 혈소판 및 혈구세포 응집정도는 CONTROL군이 가장 심했고, HEPARIN군은 GOTT군이나 KIST군에 비해 많았다. 결론: 이상의 결과에서 전신 헤파린 처치(HEPARIN)는 출혈경향을 증가시키면서 이물질 표면의 응고반응을 효과적으로 차단하지 못하는 반면, 헤파린 표면처리된 우회도관(GOTT & KIST)의 경우는 출혈경향 없이 표면의 응고반응을 충분히 억제하였다. 또한 국산(KIST) 헤파린 우회도관은 상용화된 외국산(GOTT)과 동등한 항혈전 성능을 보였다.

Keywords

References

  1. Science v.142 Heparin bonding on colloidal graphite surface Gott VL;Whiffen JD;Datton RC
  2. J Vasc Surg v.21 Aneurysms of the descending thoracic aorta:three hundred sixty-six consecutive cases resected without paraplegia Verdant A;Cossette R;Page A;Baillot R;Dontigny L;Page P
  3. Am J Surg v.167 Experience with thoracoabdominal aortic aneurysm resection Janusz MT
  4. Ann Chir v.45 Use of the Gott shunt in the prosthetic replacement of the aortic arch Verdant A;Page A;Baillot R
  5. J Thorac Cardiovasc Surg v.106 Experience with four surgical techniques to repair traumatic aortic pseudoaneurysm Wall JT;Boley TM;Curtis JJ;Schmaltz RA
  6. Ann Thorac Surg v.53 Blunt injuries of the thoracic aorta Hilgenberg AD;Logan DL;Akins CW(et al)
  7. Int Surg v.78 Femoro-arterial bypass using Goot shunt in liver transplantation following severe hepatic trauma Lin PJ;Jeng LB;Chen RJ;Kao CL;Chu JL;Chang CH
  8. Can J Surg v.35 Descending thoracic aortic aneurysms: surgical treatment with the Gott shunt Verdant A
  9. J Thorac Cardiovasc Surg v.99 Circulatory support during crossclamping of the descending thoracic aorta. Evidence of improved organ perfusion Cartier R;Orszulak TA;Pairolero PC;Schaff HV
  10. Ann Thorac Surg v.46 Surgery of the descending thoracic aorta: spinal cord protection with the Gott shunt Verdant A;Page A;Cossette R;Dontigny L;Page P;Baillot R
  11. Ann Thorac Surg v.60 (Updates) Surgery of the descending thoracic aorta: spinal cord protection with the Gott shunt Verdant A;Page A;Cossette R;Dontigny L;Page P;Bailloot R
  12. 대흉외지 v.13 흉부외상에 의한 하행 흉부대동맥 파열수술 치험 1례 보고 채헌;노준량
  13. 대흉외지 v.17 외상성 흉부대동맥류치험 1례 보고 안 혁;장병철;임승평
  14. 대한외상학회지 v.11 대동맥 절단증 선경;김정택;김광호;강성권;김준식;이춘수
  15. 심폐바이패스의 이론과 실제(1st ed.) 김원곤;노준량
  16. Cardiopulmonary bypass(1st ed.) Physiologic changes of cardiopulmonary bypass Komer C;Casthely PA;Bregmann D
  17. Ann Thorac Surg v.55 Heparin-cated circuits reduce the inflammatory response to cardiopulmonary bypass Gu YJ;Oeveren WV;Akkerman C;Boonstra PW;Huyzen RJ;Wildevuur CRH
  18. Ann Thorac Surg v.61 Beneficial effects of Duraflo Ⅱ heparin-coated circuits on postoperative lung dysfunction Ranucci M;Cirri S;Conti D(et al)
  19. Science v.152 Nonthrombogenic plastic surfaces Leininger RI;Cooper CW;Falb RD;Grode GA
  20. ASAIO v.15 Nonthrombogenic materials via a simple coating process Grode GA;Anderson SJ;Grotta HM;Falb RD
  21. Perfusion v.6 Principles of heparin-coating techniques Hsu LC
  22. ASAIO v.6 Nonthrombogenic polymers -Phamaceutical approaches- Kim SW;Ebert CD;Lin JY;McRea JC
  23. ASAIO v.33 Minimum heparin release rate for nonthrombogenecity Lin JY;Nojiri C;Okano T;Kim SW
  24. Biomat Med Dev Art Org v.11 A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue Larm O;Larsson R;Osslon R
  25. 대흉외지 v.17 한국산 PVC의 생물학적 안정도 및 적합성에 대한 실험적 고찰 선경
  26. Semin Thromb Hemost v.11 An objective assessment of the interaction of heparin and its fractions with human platelets Brace LD;Fareed J
  27. J Thorac Cardiovasc Surg v.105 Inhibition of platelet function by heparin John CH;Rees GM;Kovasc IB
  28. J Biomed Mat Res v.1 Metallic and plastic prosthetic devices as vascular wall subsitutes: Biophysical criteria and methods for evaluation Sawyer PN;Srinivasan S
  29. Throb Res v.8 Relationship of "new" vitamin K-dependent protein C and "old" autothrombin II-A Seegers WH